| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000033888 |
| Receipt No. | R000038650 |
| Official scientific title of the study | A non-interventional, cross-sectional study for evaluating factors relating to daily step counts and physical activity in Japanese patients with COPD |
| Date of disclosure of the study information | 2018/08/28 |
| Last modified on | 2018/08/24 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | A non-interventional, cross-sectional study for evaluating factors relating to daily step counts and physical activity in Japanese patients with COPD | |
| Title of the study (Brief title) | STEP COPD | |
| Region |
|
|
| Condition | ||
| Condition | COPD | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Elucidate the actual status of levels of physical activity in patients with COPD in Japan and explore factors related to levels of physical activity in a multicenter cross-sectional study in an actual clinical setting. |
| Basic objectives2 | Others |
| Basic objectives -Others | 1)Compare patients in whom the level of physical activity and the respiratory function correlate with other patients for any difference in the demographic factors.
2)Investigate the actual status of levels of physical activity (step counts, activity time of each activity intensity [METs], energy expenditure, inactivity time) by patient demographic in patients with COPD. 3)Examine the degree of influence of patient demographic factors that correlate with levels of physical activity in patients with COPD. 4)Assess the relationship between the prescription status of medications (by class) and levels of physical activity. |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 1)Daily step counts of patients with COPD
2)Activity time of each activity intensity (METs) in patients with COPD 3)Correlation between levels of physical activity and demographic factors in patients with COPD |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Patients who have provided written informed consent for participation in this study
2)Male and female patients aged at least 40 years at the time of enrolment who are given diagnosis of COPD by a physician 3)Patients whose respiratory function test values after bronchodilators (FEV1, FVC, IC) are available 4)Patients whose DLCO values and data on the presence/absence of emphysema by a chest CT scan are available 5)Outpatients who are able to answer the questionnaires and start measurement with an activity meter within four weeks after informed consent and measure activities for 14 consecutive days |
|||
| Key exclusion criteria | 1)Patients who have participated in any other interventional studies such as clinical trials within the past eight weeks
2)Patients determined to be inappropriate to be enrolled in this study by investigators because they cannot comply with the procedures, limitations, and requirements of this study, or for other reasons. 3)Patients with an exacerbation of COPDa within the past eight weeks 4)Patients who require home oxygen therapy (excluding those who use it only during nighttime) |
|||
| Target sample size | 500 | |||
| Research contact person | |
| Name of lead principal investigator | Shigetaka Kanda |
| Organization | AstraZeneca.KK |
| Division name | Medical, Evidence & Observational Research |
| Address | Osaka, Kita-ku, Ofuka-cho, 3-1 |
| TEL | 06-7711-3714 |
| Shigetaka.Kouda@astrazeneca.com | |
| Public contact | |
| Name of contact person | Tatsunori Jinnai |
| Organization | AstraZeneca.KK |
| Division name | Medical, Evidence & Observational Research |
| Address | Osaka, Kita-ku, Ofuka-cho, 3-1 |
| TEL | 06-7711-3714 |
| Homepage URL | |
| Tatsunori.Jinnai@astrazeneca.com | |
| Sponsor | |
| Institute | AstraZeneca.KK |
| Institute | |
| Department | |
| Funding Source | |
| Organization | AstraZeneca.KK |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | This will be conducted as a multicenter, non-interventional, cross-sectional study. Patients who have been confirmed to meet the inclusion criteria and none of the exclusion criteria of this study will be fully informed. Patients will be enrolled in the study by a continuous registration method after patients provide written informed consent. After providing informed consent, patients will answer the questionnaires and start measurement with an activity meter within four weeks. Activities will be measured for 14 consecutive days. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038650 |